Biocaptiva to Peform Ex-vivo Study to Evaluate BioCaptis Device

Biocaptiva Ltd, a company developing the BioCaptis a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management - announces the start of an ex-vivo study to determine if pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis using its BioCaptis device.

BioCaptiva, the University of the Highlands and Islands (UHI), and NHS Highland will collaborate on the research. The purpose of this study is to see if BioCaptis technology can be utilized to collect cell free DNA (cfDNA) from pleural fluid samples in large enough numbers for downstream DNA analysis . The goal is to find tumor-specific mutations that will aid in the diagnosis of pleural illness and cancer type without necessitating an invasive biopsy, as per pharmabiz. The research will be carried out in partnership with the University of the Highlands and Islands (UHI) and NHS Highland.

"The diagnosis of pleural disease is challenging, and fluid sampling is often inconclusive due to low tumour cell content, with further invasive biopsies often required, which are themselves common causes of hospital-based admission and patient morbidity, meaning there is a need for alternative non-invasive procedures," said Jeremy Wheeler, CEO of BIOCAPTIVA. Because of its ability to increase the amount of cell-free DNA (cfDNA) available for liquid biopsy testing, our BioCaptis device has the potential to significantly shorten pleural disease diagnosis times while also lowering overall risks and costs, providing patients with the best chance of a positive health outcome."